MK-5172/MK-8742 vs Sofosbuvir/PR in HCV GT1, 4 or 6 Infection

Registry ID

EUCTR2014-003836-38

Source registry

EUCTR

Status

Completed

Phase

PHASE3

Sponsor

Merck Corporation, Inc.

Start date

2015-02-16

Completion date

2016-02-16

Last update

2026-08-16

Conditions

• Hepatitis C

Summary

•To compare MK-5172A to SOF/PR in the treatment of HCV, as assessed by the proportion of subjects achieving SVR12 (Sustained Virologic Response 12 weeks after the end of all study therapy), defined as HCV RNA < LLOQ (either TD[u] or TND) 12 weeks after the end of all study therapy. •To evaluate the safety and tolerability of MK-5172A as compared to SOF/PR.

Locations

• , , Denmark
• , , Norway
• , , Poland
• , , Czechia
• , , Lithuania
• , , Spain
• , , Hungary

Related clinical trials

• Study of the Pharmacokinetics and Safety of Glecaprevir/Pibrentasvir Initiated in Pregnancy in Women With Hepatitis C With and Without HIV
• Evaluation of Patients With Liver Disease
• The Australian HCV Point-of-Care Testing Program
• Project I Test: Implementing HIV Testing in Opioid Treatment Programs
• The National Australian HCV Point-of-Care Testing Program - Minimal Dataset
• The National Australian HCV Point-of-Care Testing Program - HCV Antibody Testing Minimal Dataset

View on source registry